Gene therapy of prostate cancer: Current and future directions

N. J. Mabjeesh, H. Zhong, Jonathan W. Simons*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Prostate cancer (PCA) is the second most common cause of death from malignancy in American men. Developing new approaches for gene therapy for PCA is critical as there is no effective treatment for patients in the advanced stages of this disease. Current PCA gene therapy research strategies include cytoreductive approaches (immunotherapy and cytolytic/pro-apoptotic) and corrective approaches (replacing deleted or mutated genes). The prostate is ideal for gene therapy. It is an accessory organ, offers unique antigens (prostate-specific antigen, prostate-specific membrane antigen, human glandular kallikrein 2 etc.) and is stereotactically accessible for in situ treatments. Viral and non-viral means are being used to transfer the genetic material into tumor cells. The number of clinical trials utilizing gene therapy methods for PCA is increasing. We review the multiple issues involved in developing effective gene therapy strategies for human PCA and early clinical results.

Original languageEnglish
Pages (from-to)115-139
Number of pages25
JournalEndocrine-Related Cancer
Issue number2
StatePublished - 2002
Externally publishedYes


Dive into the research topics of 'Gene therapy of prostate cancer: Current and future directions'. Together they form a unique fingerprint.

Cite this